Tuesday, November 29, 2016 11:31:15 AM
This is a very valuable asset that Momenta has acquired. It's very hard to put a price on it until we see more action from the FDA on how it's going to handle the Bio's.
Amgen has already received approval for a substitute Humira but it only awarded them something like 6 of the nearly dozen indications that Humira has approval for. Childhood disease is limited.
Humira cover a huge market but the biosim situation is confusing at best. I expect to see Momenta sell this off in the future.
I'm still scratching my head why Shire would abandon this at this stage of the game. But again with Momenta I've scratched my head so often I have a bald spot down the middle. I do expect Momenta will have a drug to fix this situation.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM